University of British Columbia

University of Texas System

Fuqiang Ban

Marc Cox

Artem Cherkasov

Artem Tcherkassov

Paul Rennie

Evgeniia Bogomol

Anh-tien Ton

Eric J J Leblanc

Eric Joseph Jean LeBlanc

Kateryna Dunayenko

Paul S Rennie

Kush Dalal

Lavinia A Carabet

Helene Morin

Sergiy Babiy

Huifang Li

Nada Lallous

Anton V Tverdokhlebov

Kriti Singh

Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith

A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or bladder cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds are also described.

Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use

Growing community of inventors

Vancouver, Canada

Fuqiang Ban